Sanofi has followed in the footsteps of its rivals in the US insulin market with a 78% price cut for its most widely-used Lantus product starting next January. It will restrict out-of-pocket costs ...

Luckily, there are many alternative insulins, both rapid-acting and long-acting. Zilbermint highlights Lantus (insulin glargine) as a good option. Although Levermir and Lantus have different ...

GoodRx said in a statement that it is working with Sanofi to offer U.S. insulin patients a coupon for to a 30-day supply of Lantus, an insulin glargine injection and Sanofi's most widely ...

Speculation had been building for weeks with media reports suggesting the pharma giant decided against keeping its Lantus insulin production in France. “Sanofi has a long history of developing ...

Express Scripts even blocked both the branded reference product – Lantus - and the lower-priced biosimilar. There may be another impediment to Amjevita’s uptake, regardless of which version is ...

Last month, German media cited government sources as saying Sanofi had changed course after initial considerations to transfer Lantus production to France. At that time, the drugmaker had been ...

Its leading drugs include Lantus for treating diabetes and Dupixent for treating atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyps. Sanofi also acquired Provention Bio in 2023 ...

Its leading drugs include Lantus for treating diabetes and Dupixent for treating atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyps. In July 2023, Sanofi expanded an existing ...

A standard blood sugar-lowering product is Glumetza (metformin). Examples of blood sugar-lowering insulin products include ...

vial or cartridge Lantus vial or cartridge (Sanofi-Aventis) 28 days Prescribing information 70% insulin aspart protamine suspension and 30% insulin as part injection (rDNA origin) pen fill ...

The global Injection Pen Market is valued at an estimated USD 47.0 billion in 2024 and is projected to reach USD 74.1 billion ...